Editorial Response: The Contribution of Fluconazole to the Changing Epidemiology of Invasive Candidal Infections
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Mary H. White; Editorial Response: The Contribution of Fluconazole to the Changing Epidemiology of Invasive Candidal Infections, Clinical Infectious Diseas
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Taken as a whole, these results suggest that increases in C. glabrata incidences might be related to fluconazole usage, although other host and health care factors could also have an effect on this trend (37, 47, 48).”
In the citing paper
“The role of the widespread use of azoles in the shift to resistant Candida species has been largely debated and remains controversial [12].”
From Epidemiology of Candidemia in Swiss Tertiary Care Hospitals: Secular Trends, 1991–2000 (2004) · cites this paper as [12]
In the citing paper
“The risk of C. tropicalis infection is increased in the setting of neutropenia and mucositis (53, 301, 317), conditions that are common among patients with hematologic malignancies.”
From Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) · cites this paper as [317]
Citations
Cites
Goodman, J. L., Winston, D. J., Greenfield, R. A., Chandrasekar, P. H., Fox, B., Kaizer, H., Shadduck, R. K., Shea, T. C., Stiff, P., Friedman, D. J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261301 · Cited by 1,174
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937
The Epidemiology of Hematogenous Candidiasis Caused by Different Candida Species
Abi‐Said, D., Anaissie, E., Uzun, O., Raad, I., Pinzcowski, H., & Vartivarian, S. (1997) · Clinical Infectious Diseases · doi:10.1086/513663 · Cited by 755
Importance of Candida Species Other than C. albicans as Pathogens in Oncology Patients
Wingard, J. R. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.1.115 · Cited by 542
Fungemia in a Cancer Hospital: Changing Frequency, Earlier Onset, and Results of Therapy
Horn, R., Wong, B., Kiehn, T. E., & Armstrong, D. (1985) · Clinical Infectious Diseases · doi:10.1093/clinids/7.5.646 · Cited by 480
Winston, D. J., Chandrasekar, P. H., Lazarus, H. M., Goodman, J. L., Silber, J. L., Horowitz, H., Shadduck, R. K., Rosenfeld, C. S., Ho, W. G., Islam, M. Z., et al. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-7-199304010-00003 · Cited by 373
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Miller, C. B., Karp, J. E., & Saral, R. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.9.1847 · Cited by 340
Powderly, W. G., Finkelstein, D. M., Feinberg, J., Frame, P., He, W., van der Horst, C., Koletar, S. L., Eyster, M. E., Carey, J., Waskin, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503163321102 · Cited by 318
Cameron, M. L., Schell, W. A., Bruch, S., Bartlett, J. A., Waskin, H. A., & Perfect, J. R. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.11.2449 · Cited by 152
Cited by
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
“glabrata is well known (1, 10, 148, 311, 319), the evidence is strongest for cancer centers and less so for individual nonspecialty hospitals (11, 33, 131, 145, 147, 259).”
BackgroundVoriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Aspergillosis Case-Fatality Rate: Systematic Review of the Literature
Lin, S.-J., Schranz, J., & Teutsch, S. M. (2001) · Clinical Infectious Diseases · doi:10.1086/318483 · Cited by 1,409
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844
Practice Guidelines for Diseases Caused by Aspergillus
Stevens, D. A., Kan, V. L., Judson, M. A., Morrison, V. A., Dummer, S., Denning, D. W., Bennett, J. E., Walsh, T. J., Patterson, T. F., & Pankey, G. A. (2000) · Clinical Infectious Diseases · doi:10.1086/313756 · Cited by 789
Hajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W., Ciblak, M. A., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.4.1519-1527.2004 · Cited by 649
“Site Baltimore 289 (56) 391 (62) 188 (68) 98 (70) 72 (47) 680 (59) Connecticut 227 (44) 235 (38) 87 (32) 43 (30) 81 (53) 463 (41)”
BackgroundInfluentialAlmirante, B., Rodríguez, D., Park, B. J., Cuenca-Estrella, M., Planes, A. M., Almela, M., Mensa, J., Sanchez, F., Ayats, J., Gimenez, M., et al. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.4.1829-1835.2005 · Cited by 566
“TPN 125 (40) 57 (38) 7 (27) 7 (23) 3 (25) 43 (57) Catheter related 108 (31) 53 (31) 3 (10) 7 (22) 2 (17) 42 (54) Prior antibiotic therapy 298 (88) 156 (91) 21 (72) 26 (84) 10 (91) 70 (91) Prior antifungal therapy 57 (17) 12 (7) 7 (21) 4 (13) 9 (75) 20 (26) Death by day 3–7 74 (22) 42 (24) 9 (31) 11 (33) 2 (17) 5 (6) O…”
BackgroundAntifungal drug resistance of pathogenic fungi
Kontoyiannis, D. P., & Lewis, R. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08162-x · Cited by 553
Epidemiology of Candidemia in Swiss Tertiary Care Hospitals: Secular Trends, 1991–2000
Marchetti, O., Bille, J., Fluckiger, U., Eggimann, P., Ruef, C., Garbino, J., Calandra, T., Glauser, M., Tauber, M. G., Pittet, D., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/380637 · Cited by 478
The Impact of Culture Isolation of Aspergillus Species: A Hospital‐Based Survey of Aspergillosis
Perfect, J. R., Cox, G. M., Lee, J. Y., Kauffman, C. A., de Repentigny, L., Chapman, S. W., Morrison, V. A., Pappas, P., Hiemenz, J. W., Stevens, D. A., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/323900 · Cited by 458
Kao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457
Incidence, characteristics and outcome of ICU-acquired candidemia in India
Chakrabarti, A., Sood, P., Rudramurthy, S. M., Chen, S., Kaur, H., Capoor, M., Chhina, D., Rao, R., Eshwara, V. K., Xess, I., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-014-3603-2 · Cited by 454
“glabrata in the Western world can be linked to increased use of azole prophylaxis [1, 11, 15, 21].”
BackgroundFluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients
Eggimann, P., Francioli, P., Bille, J., Schneider, R., Wu, M.-M., Chapuis, G., Chiolero, R., Pannatier, A., Schilling, J., Geroulanos, S., et al. (1999) · Critical Care Medicine · doi:10.1097/00003246-199906000-00019 · Cited by 414
Epidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376
Cleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J., & Chiller, T. M. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis697 · Cited by 366
“This decline is consistent with other reports [21, 24].”
Epidemiological trends in nosocomial candidemia in intensive care
Bassetti, M., Righi, E., Costa, A., Fasce, R., Molinari, M. P., Rosso, R., Pallavicini, F. B., & Viscoli, C. (2006) · BMC Infectious Diseases · doi:10.1186/1471-2334-6-21 · Cited by 332
Bowden, R., Chandrasekar, P., White, M. H., Li, X., Pietrelli, L., Gurwith, M., van Burik, J., Laverdiere, M., Safrin, S., & Wingard, J. R. (2002) · Clinical Infectious Diseases · doi:10.1086/341401 · Cited by 335
Self-citationHachem, R., Hanna, H., Kontoyiannis, D., Jiang, Y., & Raad, I. (2008) · Cancer · doi:10.1002/cncr.23466 · Cited by 331
“krusei.(24,26,29,32,33) Investigators have identified several other risk factors for candidemia over the years, including the use of central venous catheters,”
BackgroundAn Overview of Fungal Infections
Garber, G. (2001) · Drugs · doi:10.2165/00003495-200161001-00001 · Cited by 309
“There is some evidence that the use of fluconazole prophylaxis has contributed to this shift inCandida epidemiology among cancer patients,[68,69] although the establishment of a causal relationship remains controversial.[70]”
BackgroundCysticercosis and Epilepsy: A Critical Review
Carpio, A., Escobar, A., & Hauser, W. A. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01287.x · Cited by 289
Introduction to Antifungal Drugs
Dismukes, W. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313748 · Cited by 262
Viudes, A., Pemán, J., Cantón, E., Úbeda, P., López-Ribot, J., & Gobernado, M. (2002) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-002-0822-1 · Cited by 250
Singh, N., Avery, R. K., Munoz, P., Pruett, T. L., Alexander, B., Jacobs, R., Tollemar, J. G., Dominguez, E. A., Yu, C. M., Paterson, D. L., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/345441 · Cited by 240
Trends in the Epidemiology of Invasive Fungal Infections
Warnock, D. W. (2007) · Nippon Ishinkin Gakkai Zasshi · doi:10.3314/jjmm.48.1 · Cited by 226
Empirical Fluconazole versus Placebo for Intensive Care Unit Patients: A Randomized Trial
Schuster, M. G., Edwards, J. E., Sobel, J. D., Darouiche, R. O., Karchmer, A. W., Hadley, S., Slotman, G., Panzer, H., Biswas, P., & Rex, J. H. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-2-200807150-00004 · Cited by 210
Prophylactic antifungal therapy in the intensive care unit
Weinstein, R. A., Rex, J. H., & Sobel, J. D. (2001) · Clinical Infectious Diseases · doi:10.1086/319763 · Cited by 155
“Although other factors could be operative [23], prior antifungal therapy has been strongly linked to infection caused by these species [24, 25].”
BackgroundHospenthal, D. R., Kwon-Chung, K. J., & Bennett, J. E. (1998) · Medical Mycology · doi:10.1080/02681219880000241 · Cited by 155
Lin, M., Carmeli, Y., Zumsteg, J. M., Flores, E., Tolentino, J., Sreeramoju, P., & Weber, S. G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4555-4560.2005 · Cited by 169
Neurocysticercosis in Radiographically Imaged Seizure Patients in U.S. Emergency Departments1
Ong, S., Talan, D. A., Moran, G. J., Mower, W. R., Newdow, M., Tsang, V. C. W., Pinner, R. W., & the EMERGEncy ID NET Study Group (2002) · Emerging infectious diseases · doi:10.3201/eid0806.010377 · Cited by 149
Risk Factors forCandida tropicalisFungemia in Patients with Cancer
Kontoyiannis, D. P., Vaziri, I., Hanna, H. A., Boktour, M. R., Thornby, J. I., Hachem, R. Y., Bodey, G. P., & RAAD, I. I. (2001) · Clinical Infectious Diseases · doi:10.1086/323812 · Cited by 192
Antifungal Prophylaxis for Solid Organ Transplant Recipients: Seeking Clarity Amidst Controversy
Singh, N. (2000) · Clinical Infectious Diseases · doi:10.1086/313943 · Cited by 140
Evaluation of a Quadrivalent Measles, Mumps, Rubella and Varicella Vaccine in Healthy Children
Shinefield, H. R., BLACK, S. B., Digilio, L., Reisinger, K. S., Blatter, M. M., Gress, J., Brown, M. L. H., Eves, K. A., Klopfer, S. O., Schödel, F. P., et al. (2005) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000172902.25009.a1 · Cited by 125
Hope, W. W., Morton, A., & Eisen, D. P. (2002) · Journal of Hospital Infection · doi:10.1053/jhin.2001.1131 · Cited by 130
Risk factors for albicans and non-albicans candidemia in the intensive care unit*
Chow, J. K., Golan, Y., Ruthazer, R., Karchmer, A. W., Carmeli, Y., Lichtenberg, D. A., Chawla, V., Young, J. A., & Hadley, S. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e31816fc4cd · Cited by 154
Bassetti, M., Trecarichi, E. M., Righi, E., Sanguinetti, M., Bisio, F., Posteraro, B., Soro, O., Cauda, R., Viscoli, C., & Tumbarello, M. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.01.005 · Cited by 135
Herpes Zoster in Otherwise Healthy Children
Feder, H. M., & Hoss, D. M. (2004) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000126901.88982.32 · Cited by 117
Knuf, M., Habermehl, P., Zepp, F., Mannhardt, W., KUTTNIG, M., Muttonen, P., Prieler, A., Maurer, H., Bisanz, H., Tornieporth, N., et al. (2006) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000195626.35239.58 · Cited by 112
The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia
Sobel, J. D. (2006) · Current Infectious Disease Reports · doi:10.1007/s11908-006-0016-6 · Cited by 127
An Outbreak of Varicella among Children Attending Preschool and Elementary School in Illinois
Dworkin, M. S., Jennings, C. E., Roth‐Thomas, J., Lang, J. E., Stukenberg, C., & Lumpkin, J. R. (2002) · Clinical Infectious Diseases · doi:10.1086/340868 · Cited by 93
Incidence of candidaemia and relationship with fluconazole use in an intensive care unit
Bassetti, M., Ansaldi, F., Nicolini, L., Malfatto, E., Molinari, M. P., Mussap, M., Rebesco, B., Bobbio Pallavicini, F., Icardi, G., & Viscoli, C. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp251 · Cited by 92
Renal impairment and Amphotericin B formulations in patients with invasive fungal infections
Saliba, F., & Dupont, B. (2008) · Medical Mycology · doi:10.1080/13693780701730469 · Cited by 90
Greene, R. M., Hancock, K., Wilkins, P. P., & Tsang, V. C. W. (2000) · Journal of Parasitology · doi:10.1645/0022-3395(2000)086[1001:tsmcas]2.0.co;2 · Cited by 91
“In human cysticercosis, most clinical manifestations occur when larvae invade the central nervous system, resulting in neurocysticercosis (Garcia et al., 1993; White, 1997).”
BackgroundTreatment options of invasive fungal infections in adults
Marchetti, O., Eggimann, P., Pittet, D., Glauser, M., & Calandra, T. (2006) · Swiss Medical Weekly · doi:10.4414/smw.2006.11392 · Cited by 90
Constant Low Rate of Fungemia in Norway, 1991 to 1996
Sandven, P., Bevanger, L., Digranes, A., Gaustad, P., Haukland, H. H., Steinbakk, M., & The Norwegian Yeast Study Group (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.12.3455-3459.1998 · Cited by 82
Epilepsy and Neurocysticercosis in Rural Bolivia: A Population‐based Survey
Nicoletti, A. S. Q., Bartoloni, A., Sofia, V., Bartalesi, F., Chavez, J. R., Osinaga, R., Paradisi, F., Dumas, J., Tsang, V. C. W., Reggio, A., et al. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.67804.x · Cited by 82
Chen, Y., Chang, S.-C., Luh, K.-T., & Hsieh, W. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg275 · Cited by 86
Persistence of Immunity to Varicella-Zoster Virus After Vaccination of Healthcare Workers
Saiman, L. M., LaRussa, P. S., Steinberg, S. P., Zhou, J. J., Baron, K., Whittier, S., Della‐Latta, P., & Gershon, A. A. (2001) · Infection Control and Hospital Epidemiology · doi:10.1086/501900 · Cited by 76
Kaur, S., SINGHI, P. D., Singhi, S. C., & Khandelwal, N. K. (2009) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31819073aa · Cited by 73
Study of Renal Safety in Amphotericin B Lipid Complex–Treated Patients
Alexander, B. D., & Wingard, J. R. (2005) · Clinical Infectious Diseases · doi:10.1086/429335 · Cited by 73
A comparative review of conventional and lipid formulations of amphotericin B
Robinson, R. F., & Nahata, M. C. (1999) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.1999.00220.x · Cited by 106
Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients
Herbrecht, R., Flückiger, U. M., Gachot, B., Ribaud, P., Thiébaut, A., & Cordonnier, C. (2007) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2007.06.007 · Cited by 73
Shinefield, H. R., BLACK, S. B., STAEHLE, B. O., Matthews, H., ADELMAN, T., Ensor, K., CHAN, S. L. A., Heyse, J. F., Waters, M., Chan, C. Y., et al. (2002) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200206000-00014 · Cited by 64
Tseng, H. F., Smith, N. X., Marcy, S. M., Sy, L. S., & Jacobsen, S. J. (2009) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181acf84f · Cited by 63
Lockhart, S. R., Wagner, D., Iqbal, N., Pappas, P. G., Andes, D. R., Kauffman, C. A., Brumble, L. M., Hadley, S., Walker, R., Ito, J. I., et al. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02474-10 · Cited by 61
Linden, P., Williams, P. A., & Chan, K. M. (2000) · Clinical Transplantation · doi:10.1034/j.1399-0012.2000.140409.x · Cited by 61
“, Candida glabrata and Candida krusei ) has also been reported (50, 51).”
BackgroundFungal infections in patients undergoing blood and marrow transplantation
Marr, K. A., & Bowden, R. A. (1999) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.1999.010403.x · Cited by 63
Lieberman, J. M., Williams, W. R., Miller, J. M., BLACK, S. B., Shinefield, H. R., Henderson, F. W., Marchant, C. D., Werzberger, A., Halperin, S. A., Hartzel, J. S., et al. (2006) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000220209.35074.0b · Cited by 59
Unusual form of neurocysticercosis associated with HIV infection
Delobel, P., Signaté, A., Guedj, M. E., Couppié, P., Gueye, M. L., Smadja, D., & Pradinaud, R. (2003) · European Journal of Neurology · doi:10.1046/j.1351-5101.2003.00696.x · Cited by 58
“Clinical manifestations of NCC depend on the number, size, and location of the CNS lesions and on the intensity of the host immune response (White, 1997).”
BackgroundMoretti, M. L., Trabasso, P., Lyra, L., Fagnani, R., Resende, M. R., de Oliveira Cardoso, L. G., & Schreiber, A. Z. (2013) · Medical Mycology · doi:10.3109/13693786.2012.708107 · Cited by 55
Neurocysticercosis in children
SINGHI, P. D., & Singhi, S. C. (2009) · The Indian Journal of Pediatrics · doi:10.1007/s12098-009-0139-5 · Cited by 59
FUNGAL INFECTIONS OF THE GENITOURINARY SYSTEM: MANIFESTATIONS, DIAGNOSIS, AND TREATMENT
Wise, G. J., Talluri, G. S., & Marella, V. K. (1999) · Urologic Clinics of North America · doi:10.1016/s0094-0143(05)70212-3 · Cited by 54
Varicella Infection Following Varicella Vaccination in a Liver Transplant Recipient
Levitsky, J., Te, H. S., Faust, T. W., & Cohen, S. M. (2002) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2002.20912.x · Cited by 51
Shinefield, H. R., Williams, W. R., Marchant, C. D., Reisinger, K. S., Stewart, T., Meissner, H. C., Guerrero, J., Klopfer, S. O., Schödel, F. P., & Kuter, B. J. (2005) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000172901.29621.e9 · Cited by 50
Vesikari, T., Baer, M., & Willems, P. (2007) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000250689.09396.21 · Cited by 50
ANTIFUNGAL THERAPY IN ‘BONE MARROW FAILURE’
Richardson, M. D., & Kokki, M. H. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00600.x · Cited by 52
Parslow, B. Y., & Thornton, C. R. (2022) · Microorganisms · doi:10.3390/microorganisms10061208 · Cited by 57
“Furthermore, the significant healthcare costs implicated in high antifungal use as well as severe side effects endured by recipients are also important [15,72,91].”
BackgroundMesocestoides cortiintracranial infection as a murine model for neurocysticercosis
Alvarez, J. I., Mishra, B. B., Gundra, U. M., MISHRA, P. K., & Teale, J. M. (2010) · Parasitology · doi:10.1017/s0031182009991971 · Cited by 58
“Neurocysticercosis (NCC) is an infection of the central nervous system (CNS) caused by the metacestode (larval form) of the tapeworm Taenia solium (White, 1997; White et al. 1997; Garcia and Del Brutto, 2005).”
BackgroundInfluentialSantamaria, E., Plancarte, A., & de Aluja, A. S. (2002) · Journal of Parasitology · doi:10.1645/0022-3395(2002)088[0069:teiopw]2.0.co;2 · Cited by 49
“NCC is also increasing in developed countries, such as the United States, where hundreds of patients are diagnosed each year with NCC (White, 1997).”
BackgroundGirão, E. S., Levin, A. S., Basso, M., Gobara, S., Gomes, L. B., Medeiros, E. A., & Costa, S. F. (2008) · Medical Mycology · doi:10.1080/13693780802004996 · Cited by 49
Hiemenz, J., RAAD, I. I., Maertens, J., Hachem, R. Y., Saah, A. J., Sable, C. A., Chodakewitz, J., Severino, M. E., Saddier, P., Berman, R. S., et al. (2010) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-010-1013-0 · Cited by 47
Candidemia: A Nosocomial Complication in Adults with Late‐Stage AIDS
Launay, O., Lortholary, O., Bouges‐Michel, C., Jarrousse, B., Bentata, M., & Guillevin, L. (1998) · Clinical Infectious Diseases · doi:10.1086/520291 · Cited by 47
“glabrata infections, but the contribution of fluconazole to such epidemiological changes is still controversial [47].”
BackgroundMasiá Canuto, M., Gutiérrez Rodero, F., Ortiz de la Tabla Ducasse, V., Hernández Aguado, I., Martín González, C., Sánchez Sevillano, A., & Martín Hidalgo, A. (2000) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960000323 · Cited by 46
“Selective pressure from antibiotics is an established explanation for the development of bacterial resistance to antibiotics [ 23 ].”
BackgroundShinefield, H. R., BLACK, S. B., Thear, M., Coury, D. L., Reisinger, K. S., Rothstein, E. P., Xu, J. Z., Hartzel, J. S., Evans, B., Digilio, L., et al. (2006) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000207857.10947.1f · Cited by 46
Linden, P. K., Coley, K. C., Fontes, P., Fung, J. J., & Kusne, S. (2003) · Clinical Infectious Diseases · doi:10.1086/375219 · Cited by 46
Lipid‐Based Amphotericin B for the Treatment of Fungal Infections
Slain, D. (1999) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.4.306.30934 · Cited by 46
Clinical Trials of Antifungal Prophylaxis among Patients Undergoing Surgery
Calandra, T., & Marchetti, O. (2004) · Clinical Infectious Diseases · doi:10.1086/421955 · Cited by 47
Non-albicans Candida is the most common cause of candidemia in pediatric cancer patients
Mullen, C. A., El-Baki, H. A., samir, H., Tarrand, J. J., & Rolston, K. V. I. (2003) · Supportive Care in Cancer · doi:10.1007/s00520-003-0453-9 · Cited by 46
Varicella Vaccine — The First Six Years
Arvin, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441310 · Cited by 42
Treating neurocysticercosis medically: a systematic review of randomized, controlled trials
Salinas, R. A., Counsell, C. E., Prasad, K., Gelband, H., & Garner, P. (1999) · Tropical Medicine & International Health · doi:10.1046/j.1365-3156.1999.00477.x · Cited by 40
“It has been estimated that approximately 50 million people are infected with it, although this figure is likely to be an underestimate (White 1997).”
BackgroundTherapy for neurocysticercosis
Takayanagui, O. M. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.1.129 · Cited by 41
Varicella vaccination in Australia
Macartney, K. K., Beutels, P., McIntyre, P. B., & Burgess, M. (2005) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2005.00717.x · Cited by 39
SCOTONI, A. E., de Manreza, M. L. G., & Guerreiro, M. M. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.16503.x · Cited by 39
Blood Stream Infections by Candida glabrata and Candida krusei: A Single-Center Experience
Choi, H. K., Jeong, S. J., Lee, H. S., Chin, B. S., Choi, S. H., Han, S. H., Kim, M. S., Kim, C. O., Choi, J. Y., Song, Y. G., et al. (2009) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2009.24.3.263 · Cited by 36
“Although there is a historical association between fluconazole use and the increased incidence of relatively resistant non-albicans Candida species, the degree to which fluconazole plays a role in the risk to individual patients remains unclear [17].”
BackgroundArruda, G. C., Silva, A. D. T. D., Quagliato, E. M. A. B., MARETTI, M. A., & Rossi, C. L. (2005) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2005.01480.x · Cited by 34
“Neuroimaging techniques have contributed to a more accurate diagnosis and a better understanding of the pathophysiology of neurocysticercosis (Palacios et al. 1997; White 1997; Del Brutto 1999; Noujaim et al. 1999).”
BackgroundMethodInfluentialHomans, J. D., Khoo, L. T., CHEN, T., Commins, D., Ahmed, J., & Kovacs, A. (2001) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200109000-00016 · Cited by 34
Secular trends in nosocomial candidaemia in non-neutropenic patients in an Italian tertiary hospital
Luzzati, R., Allegranzi, B., Antozzi, L., Masala, L., Pegoraro, E., Azzini, A., & Concia, E. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01268.x · Cited by 33
Ferrer, E., González, L. M., Martínez-Escribano, J. Á., González-Barderas, M., Cortéz, M. M., Dávila, I., Harrison, L. J., Parkhouse, R. M. E., & Gárate, T. (2007) · Parasitology Research · doi:10.1007/s00436-007-0507-x · Cited by 33
“This disease is a public health and economic problem in many developing countries (White 1997).”
BackgroundAmphotericin B preparations: a maximum tolerated dose in severe invasive fungal infections?
Ellis, M. E. (2000) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.2000.020203.x · Cited by 33
Prevention of infection in the immunocompromised host
Risi, G., & Tomascak, V. (1998) · American Journal of Infection Control · doi:10.1053/ic.1998.v26.a89371 · Cited by 29
New agents for the treatment of systemic fungal infections – current status
Rex, J. H., & Arıkan, S. (2002) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.7.1.3 · Cited by 31
New agents for treatment of systemic fungal infections
Arıkan, S., & Rex, J. H. (2000) · Emerging Drugs · doi:10.1517/14728214.5.2.135 · Cited by 26
Kim, S. H., Shin, J. H., Kim, E. C., Lee, K., Kim, M., Lee, W. G., Uh, Y., Lee, H. S., Lee, M., Jeong, S. H., et al. (2008) · Medical Mycology · doi:10.1080/13693780802291445 · Cited by 28
Epidemiology of nosocomial candidaemia in a university hospital: a 12-year study
Gürcüoğlu, E., Ener, B., Akalın, H., SINIRTAŞ, M., Evci, C., Akçağlar, S., Yılmaz, E., & Heper, Y. (2010) · Epidemiology and Infection · doi:10.1017/s0950268809991531 · Cited by 31
“This change is believed to be related to the introduction of fluconazole prophylaxis, but the reasons for the variability in the frequency of the different species from diverse studies remain controversial [29, 30].”
BackgroundThe emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia
Sobel, J. D. (2007) · Current Fungal Infection Reports · doi:10.1007/s12281-007-0007-6 · Cited by 26
Candidainfections in the intensive care unit: epidemiology, risk factors and therapeutic strategies
Bassetti, M., Righi, E., Tumbarello, M., Biagio, A. D., Rosso, R., & Viscoli, C. (2006) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.4.5.875 · Cited by 26
Endoscopic removal of cisternal neurocysticercal cysts
Gravori, T., Steineke, T. C., & Bergsneider, M. (2002) · Neurosurgical FOCUS · doi:10.3171/foc.2002.12.6.8 · Cited by 23
Shinefield, H. R., BLACK, S. B., STAEHLE, B. O., ADELMAN, T., Ensor, K., Ngai, A. L., White, C. J., Bird, S. R., Matthews, H., & Kuter, B. J. (1998) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199811000-00003 · Cited by 23
Nephrotoxicity of Amphotericin B Desoxycholate
Girmenia, C., Gentile, G., Micozzi, A., & Martino, P. (2001) · Clinical Infectious Diseases · doi:10.1086/322716 · Cited by 23
Seroprevalence of human Taenia solium cysticercosis in Haiti
Raccurt, C. P., Agnamey, P., Boncy, J., Henrys, J. H., & Totet, A. (2009) · Journal of Helminthology · doi:10.1017/s0022149x09232330 · Cited by 22
“Many studies from Latin America have shown that infection of the brain by the larvae of the pork tapeworm T. solium is an important cause of epileptic seizures in endemic communities (Medina et al., 1990; Garcia et al., 1993; White, 1997).”
Background
Metadata
- Authors
- White, M. H.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- White, Mary H.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-06
- Volume
- 24
- Issue
- 6
- Pages
- 1129-1130
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2126787312
- Cited by
- 151
- References
- 17
- Citations by year
- 2022: 2 · 2021: 1 · 2016: 1 · 2014: 3 · 2012: 3
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- fluconazole, invasive candidiasis, candidal infection, epidemiology, antifungal therapy, antifungal resistance
- MeSH terms
- Antifungal Agents, Candidiasis, Humans, Fluconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.